Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878039 | 0.75 | HSD17B10 (0.65) | HSD17B10LMNAALDH1A1PKMKDM4E | |
| SCHEMBL10021907 | 0.67 | CCR1 (0.41) | HSD17B10ALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL31108696 | 0.66 | ALDH1A1 (0.47) | HSD17B10LMNAALDH1A1PKMKDM4E | |
| SCHEMBL2328248 | 0.64 | HSD17B10 (0.60) | HSD17B10LMNAALDH1A1PKMKDM4E | |
| SCHEMBL4877890 | 0.64 | DRD3 (0.34) | TSHRMAPT | |
| SCHEMBL1544475 | 0.64 | HSD17B10 (0.71) | HSD17B10LMNAALDH1A1KDM4EAPOBEC3G | |
| SCHEMBL1544445 | 0.63 | HSD17B10 (0.74) | HSD17B10LMNAALDH1A1PKMKDM4E | |
| SCHEMBL8978544 | 0.63 | ALDH1A1 (1.00) | HSD17B10LMNAALDH1A1PKMKDM4E | |
| SCHEMBL2893202 | 0.63 | HSD17B10 (0.59) | HSD17B10LMNAALDH1A1PKMKDM4E | |
| SCHEMBL3105626 | 0.62 | HSD17B10 (0.53) | HSD17B10LMNAALDH1A1PKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| EP-1773844-A1 | COMPOUNDS HAVING AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006002928-A1 | COMPOUNDS HAVING AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | HSD17B10 1060/4885LMNA 4658/4885ALDH1A1 1261/4885 |
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | DRD3, SLC6A3, DRD2 | HSD17B10 3330/4885LMNA 4683/4885ALDH1A1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.